EA201990386A1 - COMPOUND AS A JAK SELECTIVE INHIBITOR AND ITS SALTS AND THERAPEUTIC USE - Google Patents

COMPOUND AS A JAK SELECTIVE INHIBITOR AND ITS SALTS AND THERAPEUTIC USE

Info

Publication number
EA201990386A1
EA201990386A1 EA201990386A EA201990386A EA201990386A1 EA 201990386 A1 EA201990386 A1 EA 201990386A1 EA 201990386 A EA201990386 A EA 201990386A EA 201990386 A EA201990386 A EA 201990386A EA 201990386 A1 EA201990386 A1 EA 201990386A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
salts
therapeutic use
selective inhibitor
jak
Prior art date
Application number
EA201990386A
Other languages
Russian (ru)
Other versions
EA039352B1 (en
Inventor
Вэньянь Чжан
Original Assignee
Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд. filed Critical Тяньцзинь Лонгбоджин Фармасьютикал Ко., Лтд.
Priority claimed from PCT/CN2017/094254 external-priority patent/WO2018019223A1/en
Publication of EA201990386A1 publication Critical patent/EA201990386A1/en
Publication of EA039352B1 publication Critical patent/EA039352B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Abstract

Описано соединение в качестве ингибитора JAK и его соли и его изомер, сольват или фармацевтически приемлемая соль, где определения (A), R, Rи n такие, как подробно описаны в спецификации. Кроме того, также описано лекарственное средство, содержащее соединение и его соли в качестве активного ингредиента, и их применение в производстве лекарственного средства для лечения связанных с JAK киназой заболеваний, таких как заболевания иммунной системы, ревматоидный артрит и опухоли.A compound is described as a JAK inhibitor and its salt and its isomer, solvate or pharmaceutically acceptable salt, where the definitions of (A), R, R and n are as described in detail in the specification. In addition, a medicament containing the compound and its salts as an active ingredient is also described, and their use in the manufacture of a medicament for the treatment of JAK kinase-related diseases, such as diseases of the immune system, rheumatoid arthritis and tumors.

EA201990386A 2017-01-19 2017-07-25 Compound as selective jak inhibitor and salts and therapeutic use thereof EA039352B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710037675 2017-01-19
PCT/CN2017/094254 WO2018019223A1 (en) 2016-07-26 2017-07-25 Compound as selective jak inhibitor, and salt and therapeutic use thereof

Publications (2)

Publication Number Publication Date
EA201990386A1 true EA201990386A1 (en) 2019-07-31
EA039352B1 EA039352B1 (en) 2022-01-17

Family

ID=67399637

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990385A EA039344B1 (en) 2017-01-19 2017-07-25 Heterocyclic compound as jak inhibitor and salts and therapeutic use thereof
EA201990386A EA039352B1 (en) 2017-01-19 2017-07-25 Compound as selective jak inhibitor and salts and therapeutic use thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201990385A EA039344B1 (en) 2017-01-19 2017-07-25 Heterocyclic compound as jak inhibitor and salts and therapeutic use thereof

Country Status (1)

Country Link
EA (2) EA039344B1 (en)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG151327A1 (en) * 2005-09-30 2009-04-30 Vertex Pharmaceuticals Incopor Deazapurines useful as inhibitors of janus kinases
DK2455382T3 (en) * 2005-12-13 2017-01-02 Incyte Holdings Corp Heteroberl substituted pyrrolo [2,3-b] pyridines and pyrrolo [2,3-b] pyrimidines as Janus kinase inhibitors
CN101374839A (en) * 2006-01-17 2009-02-25 沃泰克斯药物股份有限公司 Azaindoles useful as inhibitors of janus kinases
EP1979353A2 (en) * 2006-01-19 2008-10-15 OSI Pharmaceuticals, Inc. Fused heterobicyclic kinase inhibitors
EA017218B1 (en) * 2008-03-11 2012-10-30 Инсайт Корпорейшн Azetidine and cyclobutane derivatives as jak inhibitors
JO3041B1 (en) * 2008-07-25 2016-09-05 Galapagos Nv Novel compounds useful for the treatment of degenerative and inflammatory diseases
CA2763900A1 (en) * 2009-06-05 2010-12-09 Cephalon, Inc. Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
TWI462920B (en) * 2009-06-26 2014-12-01 葛萊伯格有限公司 Novel compound useful for the treatment of degenerative and inflammatory diseases

Also Published As

Publication number Publication date
EA039344B1 (en) 2022-01-17
EA201990385A1 (en) 2019-07-31
EA039352B1 (en) 2022-01-17

Similar Documents

Publication Publication Date Title
EA201892395A1 (en) DRUG COMPOSITIONS OF LSD1 INHIBITOR
CY1119771T1 (en) AMINOPYRIMININYLIUM COMPOUNDS AS SUSPENSIONS TOY JAK
EA201792116A1 (en) JANUS KINASE INHIBITOR
EA201892207A1 (en) INDOLKARBOXAMIDE CONNECTIONS
EA201891191A1 (en) 2-SUBSTITUTED HINAZOLIN COMPOUNDS CONTAINING A SUBSTITUTED HETEROCYCLIC GROUP AND METHODS OF THEIR APPLICATION
TR201901312T4 (en) Tetrahydronaphthalene derivatives that inhibit the Mcl-1 protein.
EA201892075A1 (en) COMBINATION OF LSD1 INHIBITORS FOR USE FOR THE TREATMENT OF SOLID TUMORS
EA201692436A1 (en) MEDICAL APPLICATION
EA202090688A1 (en) BIS-AMIDE CONNECTIONS ACTIVATING SARCOMER AND VARIANTS OF THEIR APPLICATION
EA201791289A1 (en) INHIBITORS OF CELLULAR NECROSIS AND RELATED METHODS
EA202090573A1 (en) COMPOSITIONS OF NIRAPARIBA
EA201991700A1 (en) SELECTIVE INHIBITORS JAK1
CY1121930T1 (en) THERAPEUTIC AGENTS FOR NEURODEGENERATE DISEASES
EA201790870A1 (en) TRICYCLIC TROPICOMETRIC COMPOUNDS
PH12018500432A1 (en) Heteroaryl compounds and their use as therapeutic drugs
EA201692300A1 (en) DERIVATIVES OF CARBOXAMIDE
EA202191548A1 (en) HUMAN PLASMA CALLICREIN INHIBITORS
EA201792264A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
EA202191192A1 (en) CRYSTALLINE SALTS OF PLASMA CALLICREIN INHIBITOR
ECSP19084722A (en) 5,6-FUSED BICYCLIC COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
EA201691656A2 (en) THERAPEUTIC WAYS WITH THE USE OF NORIBOGOGINE AND RELATED COMPOUNDS
EA201691058A1 (en) DERIVATIVES OF PYRROLOPIRROLON AND THEIR APPLICATION FOR THE TREATMENT OF DISEASES
EA201892213A1 (en) KINAZ INHIBITORS
EA201891319A1 (en) COMPOUNDS OF ALKYDYDYDROCHINOLINSULPHONAMIDE
EA201990386A1 (en) COMPOUND AS A JAK SELECTIVE INHIBITOR AND ITS SALTS AND THERAPEUTIC USE

Legal Events

Date Code Title Description
TB4A Correction of composition of inventors in a published eurasian patent